Endohepatology is emerging as a novel approach to liver disease assessment, with the potential to combine EUS-guided liver biopsy, portal pressure measurement, and variceal evaluation within a single session. This “one-stop shop” model could streamline diagnostic pathways and enable integrated, real-time clinical decision-making. However, this innovation comes at a time when hepatology is moving increasingly towards non-invasive testing strategies. Questions therefore remain around its appropriateness, clinical utility, and feasibility in routine practice. In this podcast, we explore whether this approach represents meaningful progress or premature adoption, examining current evidence, potential benefits, and practical challenges.
This episode is produced in collaboration with the European Society of Gastrointestinal Endoscopy (ESGE).
Host: Tom Marjot (King's College London) Guests: Juan Abraldes (University of Alberta), Hannah van Malenstein (University Hospital Leuven)
Prefer to listen on the go? This episode is also available on the following streaming platforms:
Talk Liver To Me is supported by Boehringer Ingelheim, GSK, IPSEN and Opella. Boehringer Ingelheim, GSK, IPSEN and Opella have had no input to the content of this programme.
This programme is intended for health are professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL.
COI: Tom Marjot: No conflicts of interest to declare. Juan Abraldes has reported potential conflicts of interest, including consulting fees from Madrigal Pharmaceuticals, Boehringer Ingelheim, 89Bio, Novo Nordisk, AstraZeneca, Boston Pharmaceuticals, Agomab, Biossil, Stately Bio, Bausch Health, Roche, HepQuant, and AbbVie; stock options from Biossil; speaking fees from Terumo and Ferring; research grants from Gilead Sciences (to institution); clinical trials with Surrozen, Boehringer Ingelheim, and Salix (to institution). Hannah van Malenstein has reported potential conflicts of interest, including grants and consulting fees from Boston Scientific.
EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.
